Tolvaptanis a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
*The following content is generated by AI and is for reference only.
Overview
Tolvaptan (CAS: 152719-48-7) is a selective oral vasopressin V2 receptor antagonist. Its core synthesis involves complex heterocyclic coupling to inhibit water reabsorption in the renal collecting ducts. Molecular formula: C26H35N5O4.
Application
- Hospital pharmaceutical manufacturing for hyponatremia correction.
- Autosomal Dominant Polycystic Kidney Disease (ADPKD) management.
- Clinical trials for heart failure fluid overload reduction.
Precautions
Contraindicated in anuria or severe hepatic impairment. Requires strict monitoring of serum sodium levels to prevent rapid correction. Store in cool, dry conditions below 25°C away from light.